Serum Levels of the Adipokine Zinc-α2-glycoprotein Are Decreased in Patients with Hypertension

• Published in: ISRN endocrinology 2014-02, Vol.2014
• Main Authors: Zhu, Hui Juan, Wang, Xiang qing, Pan, Hui, Gong, Feng ying, Zhang, Dian xi, Li, Nai shi, Wang, Lin jie, Yang, Hong bo
• Format: Article
• Language: English
• Subjects: Clinical Study
• ISSN: 2090-4630; 2090-4649
• DOI: 10.1155/2014/374090

Objective. Zinc- α 2-glycoprotein (ZAG) has recently been proposed as a new adipokine involved in body weight regulation. The purpose of this study is to investigate serum levels of ZAG in patients with hypertension and its association with related characteristics. Methods. 32 hypertension patients and 42 normal controls were recruited and the relationship between serum ZAG, total and high molecular weight (HMW) adiponectin, and tumor necrosis factor- α (TNF α ) determined by enzyme-linked immunosorbent assay (ELISA) and metabolic-related parameters was investigated. Results. Serum ZAG concentrations were significantly lowered in patients with hypertension compared with healthy controls (61.4 ± 32 versus 78.3 ± 42  μ g/mL, P < 0.05 ). The further statistical analysis demonstrated that serum ZAG levels were negatively correlated with waist-to-hip ratio (WHR) ( r = − 0.241 , P < 0.05 ) and alanine aminotransferase (ALT) ( r = − 0.243 , P < 0.05 ). Additionally, serum HMW adiponectin significantly decreased, while TNF α greatly increased in hypertension patients as compared with healthy controls (2.32 ± 0.41 versus 5.24 ± 1.02  μ g/mL, 3.30 ± 1.56 versus 2.34 ± 0.99 pg/mL, P < 0.05 ). Conclusions. Serum ZAG levels are significantly lowered in hypertension patients and negatively correlated with obesity-related item WHR, suggesting ZAG is a factor associated with hypertension.